Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells.

Gonzalez, Zenovia; Carlsen, Lindsey; El-Deiry, Wafik S

Gonzalez, Zenovia; Carlsen, Lindsey; El-Deiry, Wafik S.

Afiliación

Gonzalez Z; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University Providence, RI 02903, USA.
Carlsen L; St. Francis College Brooklyn, NY 11201, USA.
El-Deiry WS; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University Providence, RI 02903, USA.

Am J Cancer Res ; 13(1): 216-226, 2023.

Article en En | MEDLINE | ID: mdl-36777499

Palabras clave

Colorectal cancer; MGMT; immune checkpoint inhibitor; ipilimumab; nivolumab; temozolomide

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Am J Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google